小剂量沙利度胺治疗骨髓纤维化对外周血CD34^+细胞的影响  

Effect of low dose thalidomide on CD34^+ cells in the peripheral-blood of patients with idiopathic myelofibrosis

作　　者：王旭庚[1] 李宏[2] 田亚宁[2] 董昌虎[2] 张王刚[1] 杨惠云[1] 张瑞丽[1] 田纬[1] 蒙昕[1] 

机构地区：[1]西安交通大学第二医院血液肿瘤科,西安710004 [2]陕西中医学院第二医院病理科

出　　处：《临床血液学杂志》2010年第4期412-415,共4页Journal of Clinical Hematology

摘　　要：目的:探讨小剂量沙利度胺治疗特发性骨髓纤维化对外周血CD34+细胞的影响。方法:37例骨髓纤维化患者口服沙利度胺100mg/d,6个月为1个疗程,骨髓活检和流式细胞仪检测患者外周血CD34+细胞。结果:37例患者中有30例完成了6个月的疗程,治疗有效患者外周血CD34+细胞数量及占外周血比例明显降低。结论:沙利度胺治疗骨髓纤维化有可能作用于CD34+细胞。Objective：To explore the effect of low dose thalidomide on the peripheral blood CD34＋ cells of patients with idiopathic myelofibrosis.Method：Thirty-seven patients with IMF received thalidomide at doses of 100 mg per day for 24 weeks.Peripheral-blood CD34＋ cell counts were determined by flow cytometry and bone marrow biopsy was compared before and after treatment.Result：30 patients（81%）were able to continue treatment beyond 24 weeks.CD34＋ cell level were significantly lower in both peripheral blood and bone marrow.Conclusion：Thalidomide may influence CD34＋ cells in peripheral-blood.

关 键 词：骨髓纤维化 沙利度胺 CD34+细胞 

分 类 号：R551.3[医药卫生—血液循环系统疾病]